It recognized that TNF inhibitors share common ADEs, possibly due to impaired immune function, such as herpes zoster, and highlighted the need for careful selection of TNFis, especially in patients with concurrent malignancies, where drugs like Infliximab might be used with greater caution. Here, TNF is linked to cancer.